Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
Body weight
Glucose control
Oral semaglutide
Real-world effectiveness
Retrospective study
Type 2 diabetes
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
18 Feb 2024
18 Feb 2024
Historique:
received:
15
11
2023
accepted:
11
01
2024
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
18
2
2024
Statut:
aheadofprint
Résumé
Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. The study included 166 individuals with T2D, predominantly men (64.5%), with a mean age of 64.4 years and a mean diabetes duration of 10.1 years. In the majority of patients (68.3%) oral semaglutide was used as a second-line drug, mostly with metformin. At baseline, mean BMI was 28.9 kg/m This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting.
Identifiants
pubmed: 38369592
doi: 10.1007/s40618-024-02309-2
pii: 10.1007/s40618-024-02309-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Buckley ST, Baekdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Ronne J, Madsen KG, Scheele SG, Alanentalo T, Kirk RK, Pedersen BL, Skyggebjerg RB, Benie AJ, Strauss HM, Wahlund PO, Bjerregaard S, Farkas E, Fekete C, Sondergaard FL, Borregaard J, Hartoft-Nielsen ML, Knudsen LB (2018) Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 10:eaar7047
doi: 10.1126/scitranslmed.aar7047
pubmed: 30429357
Gallwitz B, Giorgino F (2021) Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne) 12:645507
doi: 10.3389/fendo.2021.645507
pubmed: 34267725
Rodbard HW, Dougherty T, Taddei-Allen P (2020) Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care 26:S335–S343
doi: 10.37765/ajmc.2020.88554
pubmed: 33439582
Mosenzon O, Capehorn MS, De Remigis A, Rasmussen S, Weimers P, Rosenstock J (2022) Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol 21:172
doi: 10.1186/s12933-022-01585-7
pubmed: 36056351
pmcid: 9440529
Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SO, Lingvay I, Sondergaard AL, Treppendahl MB, Montanya E (2019) Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 42:2272–2281
doi: 10.2337/dc19-0883
pubmed: 31530666
Yanai H, Hakoshima M, Adachi H, Katsuyama H (2022) A significant effect of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes. Cardiol Res 13:303–308
doi: 10.14740/cr1441
pubmed: 36405226
pmcid: 9635779
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
doi: 10.1056/NEJMoa1607141
pubmed: 27633186
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsboll T, Warren ML, Bain SC (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851
doi: 10.1056/NEJMoa1901118
pubmed: 31185157
McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB (2023) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 25:1932–1941
doi: 10.1111/dom.15058
pubmed: 36945734
Fadini GP, Frison V, Rigato M, Morieri ML, Simioni N, Tadiotto F, D’Ambrosio M, Paccagnella A, Lapolla A, Avogaro A (2020) Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetol 57:367–375
doi: 10.1007/s00592-019-01445-z
pubmed: 31673896
Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP (2023) Clinical features, cardiovascular risk profile, and therapeutic trajectories of patients with type 2 diabetes candidate for oral semaglutide therapy in the Italian specialist care. Diabetes Ther 14:2159–2172
doi: 10.1007/s13300-023-01490-6
pubmed: 37848758
pmcid: 10597935
Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I (2021) Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab 23:2177–2182
doi: 10.1111/dom.14453
pubmed: 34060209
pmcid: 8453868
Frazer M, Swift C, Gronroos NN, Sargent A, Leszko M, Buysman E, Alvarez S, Dunn TJ, Noone J, Guevarra M (2023) Real-world hemoglobin A1c changes, prescribing provider types, and medication dose among patients with type 2 diabetes mellitus initiating treatment with oral semaglutide. Adv Ther 40:5102–5114
doi: 10.1007/s12325-023-02677-w
pubmed: 37740832
pmcid: 10567941
Candido R, Gaiotti S, Giudici F, Toffoli B, De Luca F, Velardi V, Petrucco A, Gottardi C, Manca E, Buda I, Fabris B, Bernardi S (2023) Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes. J Clin Med 12:6052
doi: 10.3390/jcm12186052
pubmed: 37762991
pmcid: 10532177
Yamada H, Yoshida M, Funazaki S, Morimoto J, Tonezawa S, Takahashi A, Nagashima S, Masahiko K, Kiyoshi O, Hara K (2023) Retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in Japanese clinical settings. J Cardiovasc Dev Dis 10:176
pubmed: 37103055
pmcid: 10141082
(2021) Veneto Region: Code of conduct for the use of health data for teaching and scientific publication purposes. https://www.garanteprivacyit/home/docweb/-/docweb-display/docweb/9535354 . Last access on Oct 2023
McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay I (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63:473–485
doi: 10.1007/s00125-019-05065-8
pubmed: 31897524
pmcid: 6997246
American Diabetes Association Professional Practice Committee (2024) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care 47:S145–S157
Jung H, Tittel SR, Schloot NC, Heitmann E, Otto T, Lebrec J, Pavel M, Lanzinger S (2023) Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the Diabetes Prospective Follow-Up Registry. Diabetes Obes Metab 25:1813–1822
doi: 10.1111/dom.15038
pubmed: 36855221
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodriguez AF, Gonzalez-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Diaz Gonzalez-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573
doi: 10.1136/bmj.m4573
pubmed: 33441402
pmcid: 7804890
Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ (2021) Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep Med 2:100387
doi: 10.1016/j.xcrm.2021.100387
pubmed: 34622228
pmcid: 8484505
Russo G, Di Bartolo P, Candido R, Lucisano G, Manicardi V, Giandalia A, Nicolucci A, Rocca A, Rossi MC, Di Cianni G (2023) The AMD ANNALS: a continuous initiative for the improvement of type 2 diabetes care. Diabetes Res Clin Pract 199:110672
doi: 10.1016/j.diabres.2023.110672
pubmed: 37084893
Vitale C, Rosano GM, Prasad K (2016) Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. Cardiovasc Diabetol 15:55
doi: 10.1186/s12933-016-0379-4
pubmed: 27039303
pmcid: 4818902